近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.12.03 | -4.41 | 4.72 | -2863.13 | | 2025.12.02 | 3.51 | 7.62 | -3879.09 | | 2025.12.01 | 5.17 | 1.38 | 33.52 | | 2025.11.28 | 5.04 | 4.54 | 1866.57 | | 2025.11.27 | -4.44 | 9.03 | -6825.52 | | 2025.11.26 | 5.06 | 5.12 | -844.61 | | 2025.11.25 | 4.90 | 0.32 | 552.16 | | 2025.11.24 | 5.15 | 3.80 | 540.69 | | 2025.11.21 | 2.19 | 2.95 | -433.17 | | 2025.11.20 | 0.88 | 2.21 | 0.68 | （文章来源：证券时报网） 龙虎榜数据显示，该股因连续三个交易日内，收盘价涨幅偏离值累计达到12%的S ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-066 号 中珠医疗控股股份有限公司 股票交易异常波动的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）股票于2025 年11月28日、12月1日、12月2日连续三个交易日内日收盘价格涨幅偏离值累计达到12%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 其他风险警示的风险：截至2024年度期末，因珠海中珠集团股份有限公司及其 关联方资金占用问题尚未解决，公司股票继续被实施其他风险警示。 业绩亏损的风险：截至本公告披露日，公司最近连续三个会计年度归属于上市 公司股东的扣除非经常性损益后的净利润均为负值。2024年度，归属于上市公司股东 的扣除非经常性损益的净利润-62,386.69万元。 业绩承诺兑现的风险：因深圳市一体医疗科技有限公司2017年度未完成承诺业 绩，补偿方深圳市一体投资控股集团有限公司、深圳市一体正润资产管理有限公司（已 更名深圳市 ...

Core Viewpoint - ST Zhongzhu's stock experienced a significant price fluctuation, with a cumulative increase of 12% over three consecutive trading days, prompting an announcement regarding abnormal trading conditions [1] Group 1: Stock Performance and Trading Conditions - The stock price deviation reached a cumulative increase of 12% over the trading days of November 28, December 1, and December 2, 2025, which is classified as abnormal trading behavior according to Shanghai Stock Exchange regulations [1] - The company conducted a self-examination and confirmed with its largest shareholder, Shenzhen Landi Technology Development Co., Ltd., that there are no undisclosed significant information affecting stock price fluctuations [1] Group 2: Shareholder Actions and Agreements - Shareholders holding more than 5% of the company's stock, Guangzhou Yunying Capital Management Co., Ltd. and Zheng Zixian, signed a share transfer agreement with Gongqingcheng Meihua Tenglong Qifei Investment Partnership to transfer a total of 10.38% of the company's shares, although this transfer has not yet been completed [1] - The controlling shareholder of the largest shareholder, Shenzhen Shenshang Holding Group Co., Ltd., plans to transfer 100% of its stake in Landi Technology to Suzhou Bubugao Investment Development Co., Ltd., which is also pending completion [1] Group 3: Financial Performance and Risks - As of the end of the 2024 fiscal year, the company continues to face risk warnings due to fund occupation issues, with net profits for the last three accounting years (excluding non-recurring gains and losses) being negative, amounting to -62.39 million yuan for 2024 [1] - The company holds a total debt claim of 313.34 million yuan against Shenzhen Yiti Medical Technology Co., Ltd., which has not fulfilled its performance commitments since 2017, and the compensation party has not fully met its obligations, with only 4.04 million yuan recovered to date [1] - As of the end of 2024, the balance of fund occupation by Zhuhai Zhongzhu Group Co., Ltd. and its related parties is 56.80 million yuan, and the company has initiated legal proceedings for recovery and applied for compulsory enforcement, although some repayment commitments remain unfulfilled [1]

关于下属公司收到民事裁定书的公告 特别提示 证券代码：600568 证券简称：ST 中珠 公告编号：2025-065 号 中珠医疗控股股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）下属深圳 市一体医疗科技有限公司（以下简称"一体医疗"）于 2025 年 11 月 29 日收到河 南省濮阳市中级人民法院（以下简称"濮阳中院"）出具的《民事裁定书》（（2025） 豫 09 民终 1336 号），因一体医疗与濮阳市第五人民医院（以下简称"濮阳五院"） 合同纠纷一案，濮阳中院已做出二审判决。具体内容如下： 一、本次诉讼的基本情况 2015 年 11 月 30 日，一体医疗与被告濮阳五院签订了《关于共同成立肿瘤 诊疗中心的合作协议》双方约定成立濮阳市第五人民医院"肿瘤诊疗中心"，自 主经营，自负盈亏，医院统一收费，独立核算。在合作过程中，濮阳五院未按双 方约定支付回购款，经一体医疗多次催促仍未支付。 为维护一体医疗的合法权益，一体医疗向河南省濮阳市 ...

Market Overview - On December 1, the medical services sector rose by 0.68% compared to the previous trading day, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Medical Services Sector - ST Zhongzhu (600568) closed at 2.85, up 5.17% with a trading volume of 230,800 shares and a turnover of 64.91 million yuan [1] - Haoyuan Pharmaceutical (688131) closed at 78.45, up 3.21% with a trading volume of 30,400 shares and a turnover of 238 million yuan [1] - Kanglong Chemical (300759) closed at 29.66, up 2.45% with a trading volume of 189,900 shares and a turnover of 563 million yuan [1] Top Losers in Medical Services Sector - Bid Pharma (688073) closed at 69.33, down 4.70% with a trading volume of 10,800 shares and a turnover of 75.39 million yuan [2] - Chengda Pharmaceutical (301201) closed at 45.90, down 4.26% with a trading volume of 116,700 shares [2] - Yaokang Bio (688046) closed at 16.40, down 4.21% with a trading volume of 36,600 shares and a turnover of 60.80 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 152 million yuan from institutional investors, while retail investors saw a net inflow of 88.82 million yuan [2] - Notable stocks with significant capital inflow include Innovation Medical (002173) with a net inflow of 29.99 million yuan from institutional investors [3] - Conversely, stocks like Bid Pharma (688073) faced a net outflow of 63.70 million yuan from institutional investors [3]

Core Viewpoint - ST Zhongzhu announced new developments in a contract dispute involving its subsidiary Yiti Medical and Puyang Fifth Hospital, with the case amounting to 32.7035 million yuan [1] Summary by Relevant Sections - **Legal Proceedings** - Yiti Medical received a second-instance civil ruling from Puyang Intermediate Court on November 29, 2025, regarding the contract dispute [1] - The first-instance ruling had annulled the cooperation agreement and rejected other claims from Yiti Medical, which led to an appeal [1] - Puyang Intermediate Court found that the basic facts of the first-instance ruling were unclear, thus revoking the original judgment and sending the case back for retrial [1] - **Financial Implications** - The case involves a disputed amount of 32.7035 million yuan [1] - Yiti Medical has been refunded the prepayment of 200,200 yuan for the second-instance handling fee due to the retrial [1] - The company has stated that it is currently unable to confirm the impact on its profits due to the ongoing retrial and will disclose further developments in a timely manner [1]

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for the sector in the next 6-12 months [9][63]. Core Insights - The medical services sector has shown resilience, with a recent performance boost attributed to the seasonal increase in flu cases, despite ongoing cost control pressures from medical insurance [9][63]. - The report highlights the significance of the recent government initiative to promote provincial-level medical insurance coordination, which is expected to enhance the efficiency of fund utilization and improve the overall healthcare system [5][6][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 31.62, with a Price-to-Book (PB) ratio of 3.18, indicating a slight increase from the previous week [4][29]. Summary by Sections Industry Performance - The pharmaceutical and biological sector experienced a decline of 2.67% this week, ranking 17th among 31 primary industries [2][11]. - The medical services sub-sector reported a slight increase of 1.42%, closing at 6237.83 points [22][23]. Company Performance - Top-performing companies in the medical services sector include ST Zhongzhu (+16.3%), Baihua Pharmaceutical (+11.6%), and Lanwei Medical (+10.6%) [3][27]. - Underperforming companies include Aier Eye Hospital (-1.6%) and WuXi AppTec (-0.7%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.40 from the previous week, while the PB ratio has risen by 0.04 [4][29]. - The maximum and minimum PE ratios over the past year were 41.13 and 28.46, respectively, indicating a relatively stable valuation range [4][29]. Government Policy Impact - The recent government meeting emphasized the importance of provincial-level medical insurance coordination, which aims to balance fund distribution across regions and enhance the overall healthcare system [5][6][61]. - The report identifies structural opportunities for the pharmaceutical industry, particularly in innovative drugs, medical devices, and healthcare information technology, as a result of the new insurance policies [6][62]. Investment Recommendations - The report suggests focusing on high-growth areas such as pharmaceutical outsourcing services and companies with improving profit margins, including WuXi AppTec and Aier Eye Hospital [9][63].

证券代码：600568 证券简称：ST 中珠 公告编号：2025-064 号 中珠医疗控股股份有限公司 关于股票交易风险提示公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）股票价格近期存 在大幅波动的风险，敬请广大投资者审慎理性决策，注意二级市场交易风险。现提示重 要内容如下： 一、关于公司第一大股东之股东股权发生变化的风险 2025年11月23日，公司第一大股东深圳市朗地科技发展有限公司（以下简称"朗地 科技"）控股股东深圳市深商控股集团股份有限公司（以下简称"深商控股"）与苏州 步步高投资发展有限公司（以下简称"苏州步步高"）签署了《关于深圳市朗地科技发 展有限公司之股权转让协议》，根据协议，深商控股拟将其持有的朗地科技100%股权转 让给苏州步步高。本次股权转让完成后，朗地科技控股股东由深商控股变更为苏州步步 高。本次权益变动属于公司第一大股东之股东转让股份，不会导致公司第一大股东发生 变化，不触及要约收购，公司无控股股东及实际控制人的情形未发生变 ...

特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）董事会于2025年11月27日收到公司董事武 有先生、独立董事张霞女士送达的书面辞职报告。 武有先生因个人原因，申请辞去公司董事、董事会审计委员会委员、董事会薪酬与考核委员会委员职 务。辞职后，武有先生不再担任公司任何职务。 张霞女士因个人原因，申请辞去公司独立董事、董事会战略委员会委员、董事会审计委员会召集人、董 事会提名委员会委员、董事会薪酬与考核委员会委员职务。辞职后，张霞女士不再担任公司任何职务。 中珠医疗控股股份有限公司 武有先生和张霞女士在公司任职期间恪尽职守、勤勉尽责，本公司及董事会对武有先生和张霞女士在公 司任职期间为公司发展所做出的贡献表示衷心感谢！ 根据《公司法》《公司章程》《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指引 第1号一一规范运作》等相关规定，武有先生和张霞女士的离任未导致公司董事会成员低于法定最低人 数。 特此公告。 张霞女士的离任将导致公司董事会 ...

中珠医疗控股股份有限公司 关于公司董事、独立董事离任的公告 特别提示 证券代码：600568 证券简称：ST 中珠 公告编号：2025-063 号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》《公司章程》《上市公司独立董事管理办法》《上海证券交易 所上市公司自律监管指引第 1 号——规范运作》等相关规定，武有先生和张霞女 士的离任未导致公司董事会成员低于法定最低人数。 张霞女士的离任将导致公司董事会中独立董事所占比例少于三分之一，在补 选完成前，张霞女士仍需按照相关法律法规等要求继续履行职责。 武有先生、张霞女士的离任将导致董事会审计委员会成员人数低于法定人数， 在补选完成前，武有先生和张霞女士仍需按照相关法律法规等要求继续履行职责。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）董事会于 2025年11月27日收到公司董事武有先生、独立董事张霞女士送达的书面辞职报告。 武有先生因个人原因，申请辞去公司董事、董事会审计委员会委员、董事会 薪酬与考核委员会委员职务。辞职后，武有先生不再担任公司任何职 ...